|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This manuscript also provides a brief update on the organization of the renin-angiotensin-aldosterone system and other angiotensin-II-forming pathways with special relevance to heart failure.
|
8835867 |
1996 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess whether renin-angiotensin-aldosterone (RAA) system gene polymorphisms shown to be associated with alterations in the activity of the system, may predict cardiac function changes subsequent to initiating medical therapy in heart failure.
|
12031704 |
2002 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, half of the patients in all three age groups with heart failure and kidney disease received treatment with renin-angiotensin-system inhibitors; about two out of five patients received beta-blockers, while prescription rates of aldosterone inhibitors were low.
|
30187290 |
2018 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elderly heart failure with reduced ejection fraction patients (≥75 years) received significantly fewer beta-blockers (77.8% vs. 84.2%), renin-angiotensin system inhibitors (75.2% vs. 89.7%), mineralocorticoid receptor antagonists (50.6% vs. 59.6%) and ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared to patients aged less than 60 years (<i>P</i><sub>for all trends</sub> < 0.01).
|
30866680 |
2019 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure.
|
16962475 |
2006 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the renin-angiotensin system in heart failure and hypertrophy--studies in human hearts and transgenic rats.
|
7713116 |
1994 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although clinical trials have shown that the plasma renin-angiotensin system (RAS) activation decreases HF functional status and increases hospitalization for HF patients, the effect of intrarenal RAS activity is still unknown.
|
29521315 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elderly, patients with chronic kidney disease (CKD) and patients with heart failure who continue using renin-angiotensin-aldosterone-system (RAAS) inhibitors, diuretics, or non-steroidal-anti-inflammatory drugs (NSAIDs) during times of fluid loss have a high risk of developing complications like acute kidney injury (AKI).
|
31801476 |
2019 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our studies linked mechanotransduction which involved renin-angiotensin system that mediated up-regulation of Piezo1 to a clinically relevant heart failure.
|
28670382 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.
|
30512100 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
As the most widely studied and commonly applied natriuretic peptide (NP), B-type natriuretic peptide (BNP) has the effects of diuresis, natriuresis, vasodilation, anti-hypertrophy, and anti-fibrosis and it inhibits the renin-angiotensin-aldosterone and sympathetic nervous systems to maintain cardiorenal homeostasis and counteract the effects of HF.
|
29922182 |
2018 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies on polymorphisms of the renin-angiotensin-aldosterone system (RAAS), adrenergic receptor polymorphisms, endothelin (receptor) polymorphisms, and a group of miscellaneous polymorphisms that may be involved in the development or phenotypic expression of heart failure will be reviewed.
|
15545741 |
2005 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery.
|
30367208 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
|
31512149 |
2020 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since overactivity of the renin-angiotensin system contributes to the progression of heart failure, this investigation assessed changes in gene expression of ACE2, ACE, AT1 receptor and renin in the human failing heart.
|
15151696 |
2004 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACEi) and mineralocorticoid receptor (MR) antagonists are FDA-approved drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) and are used to treat heart failure.
|
27881412 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased sympathetic nerve activity and the activation of the central renin-angiotensin system are commonly associated with cardiovascular disease states such as hypertension and heart failure, yet the precise mechanisms contributing to the long-term maintenance of this sympatho-excitation are incompletely understood.
|
28549782 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cardiac release of NPs ANP and BNP represents an important compensatory mechanism during acute and chronic cardiac overload and during the pathogenesis of heart failure where their actions counteract the sustained activation of renin-angiotensin-aldosterone and other neurohormonal systems.
|
29411335 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although some conventional drugs, such as β-blockers and renin-angiotensin-aldosterone system (RAAS) inhibitors, have been shown to alleviate cardiac fibrosis in clinical trials, these traditional therapies do not tend to target all the fibrosis-associated mechanisms, and do not hamper the progression of cardiac fibrosis in patients with heart failure.
|
29497382 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies in the 1980s and 1990s demonstrated that inhibition of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors improved symptoms and mortality in HF resulting from systolic dysfunction, thus providing a framework to consider the use of β-blockers for HF therapy, contrary to the prevailing wisdom of the time.
|
24286577 |
2014 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulation of the renin-angiotensin system, particularly inhibition of the angiotensin-converting enzyme (ACE), has become a prime strategy in the treatment of hypertension and heart failure.
|
12700890 |
2003 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease.
|
31370961 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction.
|
29952095 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
|
31537750 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associated factors of HRV included advanced CKD, diabetes mellitus, serum albumin, severe proteinuria, Beck Anxiety Inventory score, erythropoietin use, renin-angiotensin system inhibitors and heart failure.
|
30328166 |
2019 |